CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 314 enrolled
Drug / intervention
Tofacitinib +1 moredrug
Likely dose
Tofacitinib 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03981900
NCT03981900N/ACompleted
CompareCT.gov

IDentification of Predictive Factors of Continuation of Treatment With Tofacitinib in Patients With Rheumatoid Arthritis in Common Practice and the Impact of the Patient's Behavioural Strategies on Clinical Parameters: The DeFacTo Study.

Pfizer·observational·Posted Jun 11, 2019·Updated Oct 1, 2024

In Brief

An observational study evaluating Tofacitinib for Arthritis, Rheumatoid. Completed, enrolled 314 participants across 66 sites.

Detailed Summary

Regarding Tofacitinib, newly introduced on the market, few data on drug retention and no data on the factors predictive of Tofacitinib drug survival in patients with RA are available. Therefore, the primary objective of the DeFacTo study will be to identify the factors predictive of Tofacitinib drug survival in patients with RA. As secondary objectives, the impact of behavioural strategies on drug survival and other clinical parameters as well as Tofacitinib effectiveness and tolerability will be studied under real-life conditions of use in French patients with RA.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsArthritis, Rheumatoid
CountriesFrance
Collaborators--

Timeline

N/ACompletedFinished
20192020202120222023202420252026
First PostedJun 11, 2019
Enrollment StartJan 4, 2019
Primary CompletionFeb 6, 2023
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 7.1 years ago

Interventions

Tofacitinibdrug

5 mg BID, oral administrtaion

Tofacitinibdrug

tablet form 11mg once daily oral